Xenon Pharmaceuticals (NASDAQ:XENE) Insider Andrea Difabio Sells 1,342 Shares

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insider Andrea Difabio sold 1,342 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $55.23, for a total transaction of $74,118.66. Following the transaction, the insider directly owned 7,301 shares of the company’s stock, valued at $403,234.23. This represents a 15.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Andrea Difabio also recently made the following trade(s):

• On Tuesday, March 10th, Andrea Difabio sold 2,607 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $60.11, for a total value of $156,706.77.

Xenon Pharmaceuticals Stock Down 4.6%

Shares of XENE opened at $55.23 on Friday. Xenon Pharmaceuticals Inc. has a 12-month low of $26.74 and a 12-month high of $63.95. The firm has a market capitalization of $4.59 billion, a price-to-earnings ratio of -12.67 and a beta of 0.91. The stock’s 50-day moving average price is $43.71 and its 200 day moving average price is $41.92.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same quarter in the previous year, the business earned ($0.84) earnings per share. Equities research analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Elevation Point Wealth Partners LLC acquired a new stake in Xenon Pharmaceuticals in the 2nd quarter valued at $32,000. Danske Bank A S acquired a new position in Xenon Pharmaceuticals during the third quarter worth $32,000. Blue Trust Inc. raised its stake in Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 717 shares in the last quarter. Kestra Advisory Services LLC bought a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at $33,000. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Xenon Pharmaceuticals during the third quarter valued at $39,000. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals News Roundup

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase‑3 progress — Xenon completed the X‑TOLE2 Phase 3 study, placing XEN1101 (azetukalner) in focus for epilepsy investors and supporting a planned NDA timeline; this derisks the lead program and underpins longer‑term commercial value. Read More.
• Positive Sentiment: Big institutional interest — Reports note major funds increasing exposure (including a ~$200M position cited by The Motley Fool), which can add buying pressure into the stock on further positive catalysts. Read More.
• Positive Sentiment: Balance‑sheet boost — Xenon closed an upsized public offering that raised approximately $747.5M of gross proceeds, extending runway for Phase 3/commercial preparations and reducing near‑term financing risk. Read More.
• Positive Sentiment: Analyst upgrades — Several brokers raised price targets and reiterated Buy/Overweight ratings (Deutsche Bank, HC Wainwright, Wells Fargo and others), which can support short‑term demand. Read More.
• Neutral Sentiment: Model adjustments — HC Wainwright revised multi‑year EPS forecasts (improving FY2028–FY2030 assumptions but nudging FY2027), reflecting evolving commercialization timing; useful for context but subject to change. Read More.
• Neutral Sentiment: Volume and momentum — The stock has seen elevated trading volume following the analyst activity and trial news, which can amplify intraday moves in either direction. Read More.
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (hundreds of thousands of shares by the CEO), reducing insider ownership and raising optics concerns for some investors. Read More.
• Negative Sentiment: Dilution risk — The sizable share issuance (and initial underwriter option) that funded the ~$747.5M raise increases outstanding shares and can pressure near‑term per‑share metrics despite improving cash runway. Read More.

Analyst Upgrades and Downgrades

Several research analysts recently commented on XENE shares. JPMorgan Chase & Co. raised their target price on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Chardan Capital raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, January 9th. Jefferies Financial Group set a $100.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday. Finally, Wedbush upped their target price on shares of Xenon Pharmaceuticals from $47.00 to $64.00 and gave the company an “outperform” rating in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $71.94.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.